EDN1 and cardiac hypertrophy: Sarpogrelate has been reported to suppress Ang II-, endothelin-1- or phenylephrine-induced cardiac hypertrophy in cultured cardiomyocytes in addition to attenuating systolic dysfunction in mice subjected to transverse aortic constriction [169].